Thrombosis Research
Volume 126, Issue 2 , Pages e154-e156 , August 2010

Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP

  • Anna Maria Lombardi

      Affiliations

    • Internal Medicine, Dept. of Medical and Surgical Sciences, University of Padova, Padova, Italy
    • Corresponding Author InformationCorresponding author. Internal Medicine, Dept of Medical and Surgical Sciences University of Padova, via Ospedale 105, 35128 Padova, Italy. Tel.: +39 049 8212168/8218296; fax: +39 049 8211391.
    • ,
  • Giulia Berti de Marinis

      Affiliations

    • Internal Medicine, Dept. of Medical and Surgical Sciences, University of Padova, Padova, Italy
    • ,
  • Raffaella Scandellari

      Affiliations

    • Internal Medicine, Dept. of Medical and Surgical Sciences, University of Padova, Padova, Italy
    • ,
  • Francesca Magalini

      Affiliations

    • Dept. of Internal Medicine, University of Parma, Parma, Italy
    • ,
  • Paolo Sansoni

      Affiliations

    • Dept. of Internal Medicine, University of Parma, Parma, Italy
    • ,
  • Pier Ferruccio Ballerini

      Affiliations

    • Internal Medicine Unit 2, Conegliano Hospital, Treviso, Italy
    • ,
  • Silvia Vettore

      Affiliations

    • Internal Medicine, Dept. of Medical and Surgical Sciences, University of Padova, Padova, Italy
    • ,
  • Nicole Candeo

      Affiliations

    • Internal Medicine, Dept. of Medical and Surgical Sciences, University of Padova, Padova, Italy
    • ,
  • Piero Marson

      Affiliations

    • Blood Transfusion Unit, Padova Hospital, Padova, Italy
    • ,
  • Giustina De Silvestro

      Affiliations

    • Blood Transfusion Unit, Padova Hospital, Padova, Italy
    • ,
  • Fabrizio Fabris

      Affiliations

    • Internal Medicine, Dept. of Medical and Surgical Sciences, University of Padova, Padova, Italy

Received 9 October 2009 ,Accepted 4 February 2010.

References 

  1. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  2. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103
  3. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584
  4. Tsai HM, Raoufi M, Zhou W, Guinto E, Grafos N, Ranzurmal S, et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2006;95:886–892
  5. Scheiflinger F, Knöbl P, Trattner B, Plaimauer B, Mohr G, Dockal M, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241–3243
  6. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–397
  7. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932–1937
  8. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost. 2009;101:233–238
  9. Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol. 2004;77:171–176
  10. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93:232–239
  11. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129:93–100
  12. Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol. 2009;84:418–421
  13. Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher. 2008;23:151–156
  14. Scaramucci L, Niscola P, Palumbo R, Giovannini M, Ales M, Tendas A, et al. Rapid response and sustained remission by rituximab in four cases of plasma-exchange-failed acute thrombotic thrombocytopenic purpura. Int J Hematol. 2009;89:398–399
  15. Sallah S, Husain A, Wan JY, Nguyen NP. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost. 2004;2:834–836
  16. Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizashi H, Fujimura Y, et al. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol. 2005;81:433–436
  17. Hagel S, Jantsch J, Budde U, Kalden JR, Eckardt KU, Veelken R. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab. Thromb Haemost. 2008;100:151–153
  18. Rüfer A, Brodmann D, Gregor M, Kremer Hovinga JA, Lämmle B, Wuillemin WA. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly. 2007;137:518–524
  19. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451–461
  20. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60–68
  21. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, et al. Schlemmer B; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132:66–74
  22. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92:1695–1698
  23. Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93:930–933
  24. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71:105–108
  25. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy - rare but there!. Leuk Lymphoma. 2009;50:1083–1095

PII: S0049-3848(10)00136-2

doi: 10.1016/j.thromres.2010.02.005

Thrombosis Research
Volume 126, Issue 2 , Pages e154-e156 , August 2010

Article Tools